Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Acute kidney injury due to gentamicin nephrotoxicity and specific miRNAs as biomarkers

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111529" target="_blank" >RIV/00843989:_____/25:E0111529 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/61988987:17110/25:A2603AIJ RIV/61989592:15110/25:73628137 RIV/00098892:_____/25:10158842

  • Výsledek na webu

    <a href="https://biomed.papers.upol.cz/artkey/bio-202501-0001_acute-kidney-injury-due-to-gentamicin-nephrotoxicity-and-specific-mirnas-as-biomarkers.php" target="_blank" >https://biomed.papers.upol.cz/artkey/bio-202501-0001_acute-kidney-injury-due-to-gentamicin-nephrotoxicity-and-specific-mirnas-as-biomarkers.php</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.5507/bp.2024.031" target="_blank" >10.5507/bp.2024.031</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Acute kidney injury due to gentamicin nephrotoxicity and specific miRNAs as biomarkers

  • Popis výsledku v původním jazyce

    Acute kidney injury (AKI) due to gentamicin nephrotoxicity is a significant concern in clinical medicine, particularly in patients receiving prolonged or high-dose gentamicin therapy. Gentamicin is an aminoglycoside antibiotic frequently used in the treatment of a range of bacterial infections. However, its use is associated with nephrotoxicity which can manifest as AKI. Due to this, it is crucial to diagnose promptly and manage treatment effectively. Ongoing studies are therefore focusing on non-protein-coding RNAs as potential biomarkers for AKI. Numerous microRNAs (miRNAs) have been implicated in gentamicin-induced nephrotoxicity and AKI. They participate in pathways associated with inflammation, cell death, and oxidative stress and each of these factors play critical roles in the development of gentamicin-induced kidney injury. Research studies have demonstrated changes in the expression levels of these miRNAs in response to gentamicin exposure both in vitro and in in vivo models, as well as in human clinical trials involving patients receiving gentamicin therapy. The dysregulation of these miRNAs correlates with the severity of kidney injury and may serve as sensitive biomarkers for early detection and monitoring of AKI induced by gentamicin.

  • Název v anglickém jazyce

    Acute kidney injury due to gentamicin nephrotoxicity and specific miRNAs as biomarkers

  • Popis výsledku anglicky

    Acute kidney injury (AKI) due to gentamicin nephrotoxicity is a significant concern in clinical medicine, particularly in patients receiving prolonged or high-dose gentamicin therapy. Gentamicin is an aminoglycoside antibiotic frequently used in the treatment of a range of bacterial infections. However, its use is associated with nephrotoxicity which can manifest as AKI. Due to this, it is crucial to diagnose promptly and manage treatment effectively. Ongoing studies are therefore focusing on non-protein-coding RNAs as potential biomarkers for AKI. Numerous microRNAs (miRNAs) have been implicated in gentamicin-induced nephrotoxicity and AKI. They participate in pathways associated with inflammation, cell death, and oxidative stress and each of these factors play critical roles in the development of gentamicin-induced kidney injury. Research studies have demonstrated changes in the expression levels of these miRNAs in response to gentamicin exposure both in vitro and in in vivo models, as well as in human clinical trials involving patients receiving gentamicin therapy. The dysregulation of these miRNAs correlates with the severity of kidney injury and may serve as sensitive biomarkers for early detection and monitoring of AKI induced by gentamicin.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30217 - Urology and nephrology

Návaznosti výsledku

  • Projekt

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2025

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Biomedical papers

  • ISSN

    1213-8118

  • e-ISSN

    1804-7521

  • Svazek periodika

    169

  • Číslo periodika v rámci svazku

    1

  • Stát vydavatele periodika

    CZ - Česká republika

  • Počet stran výsledku

    8

  • Strana od-do

    1-8

  • Kód UT WoS článku

    001334882700001

  • EID výsledku v databázi Scopus

    2-s2.0-86000714883